| Catalog No. | HV802046 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Human IgG1 Fc domain linked to a modified human FGF21. |
|---|
| Expression system | Mammalian Cells |
|---|
| Target | Fibroblast growth factor 21, FGF-21, FGF21, UNQ3115/PRO10196 |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q9NSA1 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -2273°C. |
|---|
| Alternate Names | CAS:2375240-92-7 |
|---|
| Background | Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
